PCM
ECYT

Prelude Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Prelude Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-44,284
Closed -$786K – 2382
2018
Q3 		$786K Sell
44,284
-7,969
-15% -$137K 0.05% 420
2018
Q2 		$721K Sell
52,253
-353
-0.7% -$4.19K 0.05% 418
2018
Q1 		$478K Buy
52,606
+9,948
+23% +$54.9K 0.03% 452
2017
Q4 		$183K Buy
42,658
+42,058
+7,010% +$200K 0.01% 631
2017
Q3 		$1K Sell
600
-700
-54% -$975 ﹤0.01% 1577
2017
Q2 		$2K Sell
1,300
-10,900
-89% -$23.4K ﹤0.01% 1539
2017
Q1 		$31K Buy
+12,200
New +$28.2K ﹤0.01% 1185
2015
Q2 		– Sell
-7,900
Closed -$49K – 2228
2015
Q1 		$49K Buy
+7,900
New +$45.6K 0.01% 1298
2014
Q4 		– Sell
-16,326
Closed -$99.5K – 2292
2014
Q3 		$99K Sell
16,326
-1,774
-10% -$12.1K 0.01% 1096
2014
Q2 		$119K Buy
18,100
+13,655
+307% +$154K 0.02% 1032
2014
Q1 		$106K Buy
+4,445
New +$64.5K 0.01% 1006

Other funds holding ECYT

OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
CA
Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Prelude Capital Management's ECYT Position: Q4 2018 in Review

Prelude Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 44,284 shares — an estimated $786K sold.

Prelude Capital Management first reported a position in ECYT in Q1 2014 and held it in 11 quarters. The position peaked at $786K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

  • Prelude Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Prelude Capital Management sold 44,284 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $786K.
  • Prelude Capital Management first reported a position in Endocyte, Inc. Common Stock in Q1 2014 and held it in 11 quarters.
  • Prelude Capital Management's Endocyte, Inc. Common Stock position peaked at $786K in Q3 2018.
  • 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Prelude Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.